FABP1 and metabolic dysfunction-associated steatohepatitis: Recently, intestinal PPARα signaling was reported to promote NASH progression through FABP1 regulation of dietary FA intake, which suggests that FABP1 is a compelling therapeutic target for NASH treatment.[34] This finding also suggests that the PPARA‐FABP1 signaling axis plays an important role in lipid metabolism.